Streetbeat News

Regulatory

NEO

NeoGenomics has received approval from New York State for its Neo Comprehensive Solid Tumor Test and NeoTYPE DNA & RNA Lung test. This approval expands access to advanced next-generation sequencing (NGS) testing, enhancing accurate pan-tumor cancer diagnosis.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:11 pm

ALLR

Allarity Therapeutics is set to receive a European patent for its DRP companion diagnostic for Stenoparib. The patent is also pending in the US, Japan, China, Australia, and India.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:10 pm

IRTC

MMM

ZVSA

ZyVersa Therapeutics, iRhythm Technologies, and 3M shares are trading higher due to positive developments. ZyVersa published promising research, iRhythm received FDA clearance, and 3M reported strong earnings and raised guidance.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:09 pm

SGMO

Sangamo Therapeutics has reached an agreement with the FDA on an accelerated approval pathway for its ST-920 treatment for Fabry disease. The company plans to submit a Biologics License Application (BLA) in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:07 pm

LXRX

Lexicon Pharmaceuticals has completed screening for its Phase 2B study of LX9211, a treatment for diabetic peripheral neuropathic pain, and expects to complete enrollment ahead of schedule. Top-line data is now anticipated in Q1 2025, earlier than previously expected.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:03 pm

FSHP

Trading for an unspecified asset was halted at 7:55 a.m. ET due to pending news. The halt indicates that significant information is expected to be released, which could impact the asset's price.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:55 am

IRTC

iRhythm Technologies' shares rose following FDA clearance for design changes to its Zio AT device.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:52 am

IBKR

Interactive Brokers has filed a Form 8-K/A to disclose revised operating results for Q3, indicating adjustments to previously reported financial data.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:49 am

SNGX

Soligenix announced that the Hong Kong Patent Office has granted a patent for 'Systems And Methods For Producing Synthetic Hypericin'. This development could enhance Soligenix's intellectual property portfolio and potentially impact its market position.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:35 am

CTSO

Cytosorbents' De Novo medical device application for DrugSorb-ATR has been accepted by the FDA, with a decision expected in 2025. The device aims to reduce bleeding in patients on ticagrelor undergoing CABG surgery.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:20 am